Nutriband receives US patent for AVERSA abuse deterrent transdermal technology

NutriBand Inc.

USPTO issued patent for 'Abuse and Misuse Deterrent Transdermal System' covering AVERSA platform.
Lead product AVERSA Fentanyl could be first abuse deterrent fentanyl transdermal system.
Expanded pipeline includes AVERSA buprenorphine and AVERSA methylphenidate.
Patents also granted in Europe, Japan, Korea, Russia, Mexico, Australia.
CEO Gareth Sheridan calls it an important milestone for Nutriband.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.